Drugs / ZD6126
ZD6126
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00065117 | Sep 2003 → Feb 2004 | colorectal cancer, metastatic neoplasm | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00065572 | Aug 2003 → Feb 2004 | renal cell carcinoma | AstraZeneca | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZD6126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00065117 ↗ |
| Known as | ANG 453 | ChEMBL registry synonym — accepted as the source's own label CHEMBL257662 ↗ |
| Known as | AZD 6126 | ChEMBL registry synonym — accepted as the source's own label CHEMBL257662 ↗ |
| Known as | ZM 445526 | ChEMBL registry synonym — accepted as the source's own label CHEMBL257662 ↗ |
| Modality | Small molecule | — CHEMBL257662 ↗ |